CellCentric
BiotechnologyWebsite
Operator of a clinical-stage cancer therapy biotechnology company intended to focus on novel drug development for specific cancers. The company's novel small-molecule inhibitors inhibit the common bro...
Valuation
$382.5M
Market implied
Share Price
N/A
Total Raised
$280.5M
Last Round
Later Stage VC (Series C)
Apr 2025
Latest Funding Round
Later Stage VC (Series C)
Apr 22, 2025
$116.5M
raised
Investors
+18 other investors